The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS. Every third year, it meets collectively with its European counterpart, ECTRIMS.
Targeting Neurodegeneration to Impart Neuroprotection in Progressive MS: Shiv Saidha, MBBCh
April 4th 2024The professor of neurology at Johns Hopkins Medicine discussed the limited impact of current therapies on retinal atrophy rates in progressive multiple sclerosis at the 2024 ACTRIMS Forum. [WATCH TIME: 5 minutes]
Analyzing Cognitive Profiles in Multiple Sclerosis and Alzheimer Disease: Le Hua, MD
March 27th 2024The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]
Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD
March 25th 2024The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]
Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD
March 24th 2024The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]
Clinical Significance of Visual System Modeling for Multiple Sclerosis Research: Shiv Saidha, MBBCh
March 21st 2024The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]
Association Between Obesity and Disease Progression in Multiple Sclerosis: Lars Alfredsson, PhD
March 19th 2024The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]
Improving MS Care Through Innovative Trial Designs: Daniel Ontaneda, MD, PhD
March 18th 2024Following the 2024 ACTRIMS Forum, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the need to build creative trials for multiple sclerosis treatments. [WATCH TIME: 3 minutes]
Consistent Real-World Efficacy of Ofatumumab Therapy for Multiple Sclerosis: Jason Freeman, MD, MBA
March 15th 2024The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Overviewing Cutting-Edge Research at 2024 ACTRIMS Forum: Daniel Ontaneda, MD, PhD
March 14th 2024The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine discussed several notable presentations and topics from the 2024 ACTRIMS Forum, highlighting advances in MS care. [WATCH TIME: 9 minutes]
Impact of Indole 3-Lactate Supplementation in Multiple Sclerosis Animal Models: Larissa Jank, MD
March 10th 2024The postdoctoral researcher in the department of neurology at Johns Hopkins School of Medicine discussed findings from a study on the impact of indole 3-lactate supplementation in animal models of multiple sclerosis. [WATCH TIME: 4 minutes]
Addressing Diversity Gaps in Neuromyelitis Optica Spectrum Disorder Research: Mirla Avila, MD
March 8th 2024The director of the Comprehensive Care MS Center at Texas Tech University Health Sciences Center talked about findings from a subgroup analysis of Hispanic or Latin patients from the N-MOmentum trial presented at ACTRIMS Forum 2024. [WATCH TIME: 3 minutes]
Switching From Anti-CD20 Therapy to Ublituximab Shows Promising Results in Phase 3b ENHANCE Trial
March 7th 2024New data from the phase 3b ENHANCE trial presented at ACTRIMS Forum 2024 demonstrated the smooth transition from intravenous anti-CD20 therapy to ublituximab in patients with multiple sclerosis.
Real-World Effectiveness and Safety of Monoclonal Antibodies in NMOSD: Amy Kunchok, MD, PhD
March 7th 2024The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]
The Intricate Relationship Between Biological Aging and Multiple Sclerosis: Yinan Zhang, MD
March 4th 2024The assistant professor of neurology at The Ohio State University Wexner Medical Center talked about results from an ongoing study assessing biological aging in patients with multiple sclerosis using epigenetic clocks and p16INK4a. [WATCH TIME: 6 minutes]
Analyzing Phase 2 CALLIPER Trial of IMU-838 for Progressive MS: Robert J. Fox, MD
March 3rd 2024The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from an interim analysis of the phase 2 CALLIPER trial assessing vidofludimus calcium in progressive multiple sclerosis. [WATCH TIME: 4 minutes]